Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 4/2016

01-08-2016 | Review

Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms

Authors: Corrado Murtas, Gian Marco Ghiggeri

Published in: Journal of Nephrology | Issue 4/2016

Login to get access

Abstract

Membranous nephropathy is a frequent cause of nephrotic syndrome in adults. In most patients, it appears as a primary renal disease but in about 20 % of cases membranous nephropathy is associated with systemic conditions such as systemic lupus erythematosus, infections or cancer, or with drug exposure. Reliable differentiation between primary and secondary membranous nephropathy has important implications for the patient, because of different therapeutic approaches between the different forms. The recent in vivo definition of glomerular targets of autoimmunity in idiopathic membranous nephropathy represented a real breakthrough and nowadays more than one podocyte antigen is considered in some way implicated in the pathogenesis of human membranous nephropathy. Specific antibodies against all these components have been detected in serum of patients and could become biomarkers of membranous nephropathy and/or of disease activity. In this brief review, we discuss the usefulness of newly described autoantibodies in the differential diagnosis of secondary membranous nephropathy. Histological clues for recognizing the two pathological entities are also analysed with regard to the available scientific evidence on this issue. Our evaluation shows that more research is needed to identify the best approach to reach a correct diagnosis of primary or secondary membranous nephropathy.
Literature
1.
2.
Glassock RJ (2010) The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 56(1):157–167CrossRefPubMed
3.
Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernandez-Juarez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernandez-Vega F, Praga M (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21(4):697–704CrossRefPubMedPubMedCentral
4.
Ponticelli C, Glassock RJ (2014) Glomerular diseases: membranous nephropathy—a modern view. Clin J Am Soc Nephrol 9(3):609–616CrossRefPubMed
5.
6.
Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J (2006) Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70(8):1510–1517CrossRefPubMed
7.
Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL (1959) Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions. Proceedings of the Society for Experimental Biology and Medicine Society. Exp Biol Med New York NY 100(4):660–664CrossRef
8.
Allegri L (1997) Antigens in experimental models of membranous nephropathy: are they involved in human disease? Nephrol Dial Transplant 12(9):1801–1804CrossRefPubMed
9.
Kerjaschki D, Farquhar MG (1983) Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157(2):667–686CrossRefPubMedPubMedCentral
10.
Adler S, Huang H (2004) Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol 287(5):F907–F913
11.
Kerjaschki D (2004) Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 364(9441):1194–1196CrossRefPubMed
12.
Murtas C, Bruschi M, Carnevali ML, Petretto A, Corradini E, Prunotto M, Candiano G, degl’Innocenti ML, Ghiggeri GM, Allegri L (2011) In vivo characterization of renal auto-antigens involved in human auto-immune diseases: the case of membranous glomerulonephritis. Proteomics Clin Appl 5(1–2):90–97CrossRefPubMed
13.
Murtas C, Allegri L, Ghiggeri GM (2013) Circulating antipodocyte antibodies in membranous nephropathy: new findings. Am J Kidney Dis 62(1):12–15CrossRefPubMed
14.
Murtas C, Ravani P, Ghiggeri GM (2011) New insights into membranous glomerulonephritis: from bench to bedside. Nephrol Dial Transplant 26(8):2428–2430CrossRefPubMed
15.
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361(1):11–21CrossRefPubMedPubMedCentral
16.
Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, Gatti R, Argentiero L, Magistroni R, Garibotto G, Scolari F, Ravani P, Gesualdo L, Allegri L, Ghiggeri GM (2011) Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics 74(10):2008–2017CrossRefPubMed
17.
Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, Bruno F, Radice A, Furci L, Argentiero L, Carnevali ML, Messa P, Scolari F, Sinico RA, Gesualdo L, Fervenza FC, Allegri L, Ravani P, Ghiggeri GM (2012) Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 7(9):1394–1400CrossRefPubMedPubMedCentral
18.
Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F, Kador P, Allegri L, Ghiggeri GM (2010) Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21(3):507–519CrossRefPubMedPubMedCentral
19.
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371(24):2277–2287CrossRefPubMedPubMedCentral
20.
Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (2011) Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22(6):1137–1143CrossRefPubMedPubMedCentral
21.
Debiec H, Ronco P (2011) PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364(7):689–690CrossRefPubMed
22.
Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA (2011) An immunofluorescence test for phospholipase-A(2)-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26(8):2526–2532CrossRefPubMed
23.
Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S (2015) Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol 19(4):653–660CrossRefPubMed
24.
Ardalan M, Ghafari A, Hamzavi F, Nasri H, Baradaran B, Majidi J, Nikbin B (2013) Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. J Nephropathol 2(4):241–248PubMedPubMedCentral
25.
Bech AP, Hofstra JM, Brenchley PE, Wetzels JF (2014) Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9(8):1386–1392CrossRefPubMedPubMedCentral
26.
Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22(8):1543–1550CrossRefPubMedPubMedCentral
27.
Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ (2011) Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6(6):1286–1291CrossRefPubMedPubMedCentral
28.
Hofstra JM, Debiec H, Short CD, Pelle T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF (2012) Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23(10):1735–1743CrossRefPubMedPubMedCentral
29.
Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA (2014) PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 9(10):e110681CrossRefPubMedPubMedCentral
30.
Hoxha E, Harendza S, Pinnschmidt HO, Tomas NM, Helmchen U, Panzer U, Stahl RA (2015) Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transplant 30(11):1862–1869CrossRefPubMed
31.
Hoxha E, Kneissler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA (2012) Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82(7):797–804CrossRefPubMed
32.
Jatem Escalante E, Segarra Medrano A, Carnicer Caceres C, Martin-Gomez MA, Salcedo Allende MT, Ostos Roldan H, Agraz Pamplona I (2015) Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Nefrologia 35(5):479–486CrossRefPubMed
33.
Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE (2013) Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83(5):940–948CrossRefPubMed
34.
Kim YG, Choi YW, Kim SY, Moon JY, Ihm CG, Lee TW, Jeong KH, Yang SH, Kim YS, Oh YJ, Lee SH (2015) Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy. Am J Nephrol 42(3):250–257CrossRefPubMed
35.
Michel PA, Dahan K, Ancel PY, Plaisier E, Mojaat R, De Seigneux S, Daugas E, Matignon M, Mesnard L, Karras A, Francois H, Pardon A, Caudwell V, Debiec H, Ronco P (2011) Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra 1(1):251–261CrossRefPubMedPubMedCentral
36.
Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS (2013) Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One 8(4):e62151CrossRefPubMedPubMedCentral
37.
Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pelle T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G (2015) Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol 26(10):2545–2558CrossRefPubMed
38.
Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H (2013) Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 28(7):1839–1844CrossRefPubMed
39.
Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, Damoiseaux JG, van Paassen P (2015) Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy. Am J Nephrol 42(1):70–77CrossRefPubMed
40.
Timmermans SA, Ayalon R, van Paassen P, Beck LH Jr, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW (2013) Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis 62(6):1223–1225CrossRefPubMed
41.
Hu SL, Wang D, Gou WJ, Lei QF, Ma TA, Cheng JZ (2014) Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis. J Nephrol 27(2):111–116CrossRefPubMed
42.
Seitz-Polski B, Dolla G, Payre C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VL, Lambeau G (2015) Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. J Am Soc Nephrol
43.
Chakera A, Lasserson D, Beck LH Jr, Roberts IS, Winearls CG (2011) Membranous nephropathy after use of UK-manufactured skin creams containing mercury. QJM 104(10):893–896CrossRefPubMed
44.
Dauvergne M, Moktefi A, Rabant M, Vigneau C, Kofman T, Burtey S, Corpechot C, Stehle T, Desvaux D, Rioux-Leclercq N, Rouvier P, Knebelmann B, Boffa JJ, Frouget T, Daugas E, Jablonski M, Dahan K, Brocheriou I, Remy P, Grimbert P, Lang P, Chazouilleres O, Sahali D, Audard V (2015) Membranous nephropathy associated with immunological disorder-related liver disease: a retrospective study of 10 cases. Medicine (Baltimore) 94(30):e1243CrossRef
45.
Fervenza FC, Downer G, Beck LH Jr, Sethi S (2011) IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am J Kidney Dis 58(2):320–324CrossRefPubMed
46.
Gunnarsson I, Schlumberger W, Ronnelid J (2012) Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis. Am J Kidney Dis 59(4):585–586CrossRefPubMed
47.
Knehtl M, Debiec H, Kamgang P, Callard P, Cadranel J, Ronco P, Boffa JJ (2011) A case of phospholipase A(2) receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis 57(1):140–143CrossRefPubMed
48.
Stehle T, Audard V, Ronco P, Debiec H (2015) Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant 30(6):1047–1050CrossRefPubMed
49.
Ronco P, Debiec H (2015) Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care. Lancet 385(9981):1983–1992CrossRefPubMed
50.
Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A, Tincani A, Pratesi F, Migliorini P, Murtas C, Franceschini F, Trezzi B, Brunini F, Gatti R, Tardanico R, Barbano G, Piaggio G, Messa P, Ravani P, Scolari F, Candiano G, Martini A, Allegri L, Ghiggeri GM (2015) Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol 26(8):1905–1924CrossRefPubMed
51.
Bruschi M, Sinico RA, Moroni G, Pratesi F, Migliorini P, Galetti M, Murtas C, Tincani A, Madaio M, Radice A, Franceschini F, Trezzi B, Bianchi L, Giallongo A, Gatti R, Tardanico R, Scaloni A, D’Ambrosio C, Carnevali ML, Messa P, Ravani P, Barbano G, Bianco B, Bonanni A, Scolari F, Martini A, Candiano G, Allegri L, Ghiggeri GM (2014) Glomerular autoimmune multicomponents of human lupus nephritis in vivo: alpha-enolase and annexin AI. J Am Soc Nephrol 25(11):2483–2498CrossRefPubMedPubMedCentral
52.
Huang CC, Lehman A, Albawardi A, Satoskar A, Brodsky S, Nadasdy G, Hebert L, Rovin B, Nadasdy T (2013) IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol 26(6):799–805CrossRefPubMed
53.
Larsen CP, Messias NC, Silva FG, Messias E, Walker PD (2013) Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26(5):709–715CrossRefPubMed
54.
Lonnbro-Widgren J, Ebefors K, Molne J, Nystrom J, Haraldsson B (2015) Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin Kidney J 8(4):433–439CrossRefPubMedPubMedCentral
55.
Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, Kigawa A, Sawada K, Imai H (2004) Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 19(3):574–579CrossRefPubMed
56.
Qu Z, Liu G, Li J, Wu LH, Tan Y, Zheng X, Ao J, Zhao MH (2012) Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 27(5):1931–1937CrossRefPubMed
57.
Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H (2015) Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the Glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One 10(9):e0138841CrossRefPubMedPubMedCentral
58.
Xie Q, Li Y, Xue J, Xiong Z, Wang L, Sun Z, Ren Y, Zhu X, Hao CM (2015) Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 41(4–5):345–353CrossRefPubMed
59.
Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D, Gallieni M, Rosner M, Ponticelli C (2015) Glomerular diseases and cancer: evaluation of underlying malignancy. J Nephrol
Metadata
Title
Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms
Authors
Corrado Murtas
Gian Marco Ghiggeri
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 4/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-016-0268-7

Other articles of this Issue 4/2016

Journal of Nephrology 4/2016 Go to the issue

Review

FSGS: from pathogenesis to the histological lesion

Review

Focal segmental glomerular sclerosis: do not overlook the role of immune response

Review

Kidney involvement in medium- and large-vessel vasculitis

Review

Markers for the progression of IgA nephropathy

Review

IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?

Review

IgG4-related nephropathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits